May 16th 2025
GLP-1 receptor agonists show promise in reducing cardiovascular risks for patients with chronic inflammatory skin diseases like psoriasis and atopic dermatitis.
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Revolutionizing Atopic Dermatitis (RAD) Conference 2025
June 6-7, 2025
Register Now!
Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient
July 26, 2025
Register Now!
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis
View More
Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?
View More
Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management
View More
Burst CME: Targeted Therapy for Optimal Psoriasis Management
View More
Differentiating Adult vs Pediatric Atopic Dermatitis
December 19th 2024A panelist discusses how atopic dermatitis presents and is managed differently in adults vs children, with adults typically experiencing more localized lesions and chronic lichenification while children tend to have more widespread involvement and acute inflammation.
Engaging Parents, Caregivers, and Schools in the Management of Pediatric Atopic Dermatitis
December 17th 2024Karan Lal, DO, MS, FAAD, discusses how building a collaborative care network between parents, caregivers, and school staff is crucial for successful management of pediatric atopic dermatitis through consistent treatment application, trigger avoidance, and emergency response planning.
Unique Challenges and Considerations for Treating Pediatric Atopic Dermatitis
December 17th 2024A panelist discusses how treating pediatric atopic dermatitis requires special attention to age-appropriate therapies, family education, adherence challenges, and the impact on children’s quality of life, including sleep and social development.
Differentiating Pediatric Atopic Dermatitis from Other Skin Conditions
December 17th 2024Karan Lal, DO, MS, FAAD, discusses how physicians can distinguish pediatric atopic dermatitis from similar skin conditions through key clinical features such as characteristic rash distribution, intense itching, and family history of atopic diseases.
Clinical Challenges in Treating Atopic Dermatitis
December 10th 2024Panelists discuss how managing atopic dermatitis presents complex clinical challenges, including treatment resistance, medication adherence, identifying triggers, and tailoring therapies to individual patient needs and disease severity.
Significant Barriers and Unmet Needs for Patients With Atopic Dermatitis
December 10th 2024Panelists discuss how patients with atopic dermatitis face numerous obstacles to optimal care, including limited access to specialists, high treatment costs, inadequate insurance coverage, and the need for more effective long-term management options.
Variation of Atopic Dermatitis Challenges in Children and Adults
December 10th 2024Panelists discuss how atopic dermatitis presents and requires different management approaches across age groups, with distinct challenges in diagnosis, treatment adherence, and quality of life impacts between pediatric and adult populations.
Measuring Atopic Dermatitis Treatment Success
December 4th 2024Gina Mangin, MPAS, PA-C, discusses how measuring atopic dermatitis treatment success requires evaluating multiple factors, including reduction in itch intensity, improvement in sleep quality, decreased flare frequency, enhanced quality of life, and visible skin healing through standardized assessment tools and patient-reported outcomes.
Assessing Atopic Dermatitis Triggers
December 4th 2024Gina Mangin, MPAS, PA-C, discusses how identifying atopic dermatitis triggers involves carefully tracking patient exposure to common irritants such as soaps, fabrics, allergens, stress, and environmental factors while monitoring symptom flare-ups to develop targeted prevention strategies.
How to Develop an Atopic Dermatitis Treatment Plan
December 4th 2024Gina Mangin, MPAS, PA-C, discusses how developing an effective atopic dermatitis treatment plan requires a personalized, multifaceted approach that combines proper skin care, trigger avoidance, topical medications, and potentially systemic therapies based on the severity of symptoms and individual patient needs.
Psychosocial Burden and Quality of Life of Patients with Atopic Dermatitis
December 3rd 2024Panelists discuss how atopic dermatitis significantly impacts patients' mental health, social relationships, and daily activities, creating substantial psychosocial burdens that can lead to anxiety, depression, and reduced quality of life.
Patient Education and Novel Topical Therapies for AD
November 22nd 2024Panelists discuss how age restrictions for PDE4 inhibitors affect treatment decisions for pediatric patients with atopic dermatitis, addressing parental concerns and highlighting the benefits of a single treatment option like roflumilast for managing overlapping inflammatory dermatologic conditions; they also explore current guidelines for corticosteroid use, the potential impact of PDE4 inhibitors on these guidelines, and the future of topical PDE4 inhibitors in dermatology, including the integration of new agents into treatment paradigms and key considerations for patient education and decision-making.
Considerations for Using Roflumilast in the Pediatric Population, and for Skin of Color
November 22nd 2024Panelists discuss how age restrictions for PDE4 inhibitors affect treatment decisions for pediatric patients with atopic dermatitis, addressing parental concerns and highlighting the benefits of a single treatment option like roflumilast for managing overlapping inflammatory dermatologic conditions; they also explore current guidelines for corticosteroid use, the potential impact of PDE4 inhibitors on these guidelines, and the future of topical PDE4 inhibitors in dermatology, including the integration of new agents into treatment paradigms and key considerations for patient education and decision-making.